Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 14/20 | 0.64 |
| ▸ | CDK2 | P24941 | 5/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518389 | 0.86 | IKBKB (0.62) | IKBKBCDK2CDK1CDK4JAK2 | |
| SCHEMBL3518983 | 0.86 | IKBKB (0.61) | IKBKBCDK2CDK1CDK4JAK2 | |
| SCHEMBL3516470 | 0.85 | IKBKB (0.70) | IKBKBCDK2CDK1CDK4 | |
| SCHEMBL3519734 | 0.82 | IKBKB (0.59) | IKBKBCDK2CDK1CDK4JAK2 | |
| SCHEMBL3517601 | 0.82 | IKBKB (0.73) | IKBKBCDK2CDK1CDK4HDAC6 | |
| SCHEMBL3518329 | 0.81 | IKBKB (0.66) | IKBKBCDK2CDK1CDK4JAK2 | |
| SCHEMBL3519740 | 0.81 | IKBKB (0.75) | IKBKBCDK2CDK1CDK4 | |
| SCHEMBL3520682 | 0.81 | IKBKB (0.67) | IKBKBCDK2CDK1CDK4JAK2 | |
| SCHEMBL3517846 | 0.80 | IKBKB (0.73) | IKBKBCDK2CDK1CDK4 | |
| SCHEMBL3521888 | 0.80 | IKBKB (0.78) | IKBKBCDK2CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | claimed |
| EP-2004638-A1 | ANILINO-PYRIMIDINE PHENYL AND BENZOTHIOPHENE ANALOGS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | WYETH (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2007120593-A1 | ANILINO-PYRIMIDINE PHENYL AND BENZOTHIOPHENE ANALOGS | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | ABCG2, CYP3A43, CYP2D6 | IKBKB 4165/4885CDK2 806/4885CDK1 2188/4885 |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | CYP2F1, CYP4B1, CYP3A4 | IKBKB 4538/4885CDK2 188/4885CDK1 618/4885 |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | HPRT1, APRT, NUDT1 | IKBKB 3482/4885CDK2 20/4885CDK1 161/4885 |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | GALE, UGGT1, UGT1A3 | IKBKB 4349/4885CDK2 660/4885CDK1 943/4885 |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | CSNK1A1, PRKX, PRKACA | IKBKB 327/4885CDK2 123/4885CDK1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.